Prelude Therapeutics expects cash runway into second quarter of 2028
PRLD•Prelude Therapeutics expects its current cash runway to extend into the second quarter of 2028, supporting data milestones across multiple programs over the next 12–24 months.
1. Cash runway and milestones
Prelude Therapeutics expects its current cash runway to extend into the second quarter of 2028. Initial proof-of-concept data for breast cancer candidate PRT13722 are anticipated in the second half of 2027, and Phase 1 enrollment is underway.




